Get the Daily Brief
Latest Biotech News
Pfizer, Valneva press regulators... Lyme vaccine hits statistical snag
Pfizer and Valneva reported Phase III Valor results showing the Lyme disease vaccine reduced cases by roughly 70–73% but missed the trial’s prespecified statistical threshold because fewer than...
Apogee’s long‑interval eczema win: durability with quarterly to semiannual dosing
Apogee Therapeutics released mid‑stage maintenance data showing its anti‑IL‑13 antibody zumilokibart maintained clinical benefit with less frequent dosing. In the Phase II maintenance readout, 75%...
Sanofi returns to T‑cell engagers: $1.2B pact for Kali’s trispecific
Sanofi struck a global license and collaboration for Kali Therapeutics’ trispecific T‑cell engager KT‑501, providing approximately $180 million in upfront and near‑term payments with more than $1...
Engineered LNPs steer mRNA to lymph nodes — liver detargeting demonstrated
Researchers at the University of Pennsylvania reported a redesigned class of lipid nanoparticles (aroLNPs) that markedly reduce liver delivery and instead concentrate mRNA in lymph nodes, boosting...
Rapid diagnostics surge: Roche’s CE mark and Diasorin’s US bet
Roche secured CE marking for its Cobas Eplex respiratory pathogen panel 3 (RP3), a multiplex molecular assay that detects up to 25 viral and bacterial respiratory targets and offers flexible...
Washington hears biotech on China: investors and experts press urgency
A delegation of biotech investors met with a congressional commission charged with safeguarding U.S. biotech competitiveness, urging policies that respond to China’s rapid gains in clinical trials...
DNA and IVD capacity builds: Artis opens synthetic DNA hub; IDT moves into clinical assays
Artis BioSolutions launched a synthetic DNA manufacturing hub in Boston using Syngoi Technologies’ enzymatic platform to shorten supply chains and support its Watertown GMP site; the company...
Immunotherapy financings: Crossbow $77M, Immutrin $86M to advance candidates
Two financings underscored capital flow into next‑generation immunotherapies. Crossbow Therapeutics closed a $77 million Series B to advance its T‑Bolt platform and first‑in‑human candidate...
Gilead pays $2.2B for Ouro T‑cell engager – Galapagos to absorb assets
Gilead agreed to buy Ouro Medicines with roughly $1.675 billion upfront and up to $500 million in milestones to acquire OM336 (gamgertamig), a BCMAxCD3 T‑cell engager being tested in autoimmune...
Novartis snaps up Pikavation for $2B – bets on mutant‑selective PI3Kα
Novartis agreed to acquire Pikavation Therapeutics (a Synnovation subsidiary) for $2 billion upfront and up to $1 billion in milestones to secure SNV4818, a pan‑mutant‑selective PI3Kα inhibitor in...
Sanofi inks $1.2B deal for Kali trispecific – $180M up front
Sanofi struck a licensing deal with Kali Therapeutics for KT‑501, a CD19/BCMA/CD3 trispecific T‑cell engager dosed in a Phase Ia trial for rheumatoid arthritis. Kali receives $180 million in...
Apogee shows long‑acting eczema edge – investors bid shares higher
Apogee Therapeutics released Phase II maintenance data for its IL‑13 antibody zumilokibart (zumi, APG‑777) showing durable skin and itch improvement with dosing every three or six months. Company...
Pfizer, Valneva vaccine cuts Lyme by ~73%…statistical miss clouds regulatory path
Pfizer and Valneva reported Phase III Valor trial results showing roughly 70–73% efficacy against Lyme disease but missed the prespecified statistical boundary in the primary analysis because...
Rivia raises $15M to scale agentic AI for trials – eyes US expansion
Swiss startup Rivia closed a $15 million Series A led by Earlybird to advance an "agentic" AI platform that unifies and structures clinical trial data in real time. CEO Erik Scalfaro said proceeds...
Crossbow raises $77M Series B – T‑bolt engagers advance to clinic
Crossbow Therapeutics closed a $77 million Series B to fund its T‑Bolt platform and advance lead candidate CBX‑250, a T‑cell engager targeting peptide‑HLA complexes for myeloid malignancies,...
Immutrin nets $86M to advance amyloidosis antibody
Immutrin, a Cambridge, UK‑based biotech cofounded by Nobel laureate Gregory Winter, raised $86 million to advance an antibody program designed to deplete protein deposits in patients with...
Aardvark pauses ARD‑201 trials – entire pipeline on hold
Aardvark Therapeutics paused two Phase II studies of its oral weight‑loss asset ARD‑201 and put its broader pipeline on hold while it conducts a comprehensive data review and engages the FDA....
Metformin‑linked mechanism may delay HIV rebound – Gladstone multiomic study
Researchers at Gladstone Institutes published multiomic analyses in Immunity identifying cell‑intrinsic and extrinsic mechanisms tied to post‑treatment HIV control and reported that metformin...
Gilead pays $2.2B for T‑cell engager: Galapagos to absorb operations
Gilead struck a front‑loaded acquisition to secure OM336, a BCMAxCD3 T‑cell engager being developed for autoimmune blood disorders. The deal pays $1.675 billion up front with up to $500 million in...
Novartis to buy Pikavation for up to $3B: SNV4818 added to breast‑cancer suite
Novartis agreed to acquire Pikavation Therapeutics, a Synnovation subsidiary, in a deal that could total roughly $3 billion and centers on SNV4818, a pan‑mutant‑selective PI3Kα inhibitor now in...